Vergier B, Beylot-Barry M, Pulford K, Michel P, Bosq J, de Muret A, Beylot C, Delaunay M M, Avril M F, Dalac S, Bodemer C, Joly P, Groppi A, de Mascarel A, Bagot M, Mason D Y, Wechsler J, Merlio J P
Department of Pathology, CHU of Bordeaux and University of Bordeaux II, France.
Am J Surg Pathol. 1998 Oct;22(10):1192-202. doi: 10.1097/00000478-199810000-00004.
Several clinical and histopathologic features of 65 CD30+ cutaneous lymphoproliferations were evaluated for their diagnostic value between CD30+ primary versus secondary cutaneous lymphomas and for their prognostic significance. Primary cutaneous disease, spontaneous regression, and absence of extracutaneous spreading (but not age < or =60 years) were associated with a better prognosis. Epithelial membrane antigen, BNH9, CD15 or CBF.78 antigen were expressed in all types of cutaneous lymphoproliferations. However, epithelial membrane antigen immunoreactivity was more frequently expressed in CD30+ secondary cutaneous large-cell lymphoma. Among CD30+ primary cutaneous large-cell lymphoma, CD15 expression was only seen in localized skin lesions. P53 expression was not associated with spontaneous regression, extracutaneous spreading, or survival. Nested reverse transcriptase-polymerase chain reaction allowed the detection of NPM-ALK transcripts in 10 of 26 CD30+ primary and in 3 of 11 secondary cutaneous large-cell lymphomas. The ALK protein was detected in only 1 of 50 primary and in 4 of 15 secondary cutaneous CD30+ lymphoproliferations. In CD30+ primary cutaneous lymphoproliferation, NPM-ALK transcripts might be expressed by very rare normal or tumoral cells that are undetectable by immunohistochemistry. However, the expression of either NPM-ALK transcripts or ALK-protein was not correlated with prognosis or age in CD30+ cutaneous lymphoproliferations.
对65例CD30+皮肤淋巴增殖性疾病的若干临床和组织病理学特征进行了评估,以探讨其在CD30+原发性与继发性皮肤淋巴瘤之间的诊断价值及其预后意义。原发性皮肤疾病、自发消退以及无皮肤外播散(但年龄≤60岁并非如此)与较好的预后相关。上皮膜抗原、BNH9、CD15或CBF.78抗原在所有类型的皮肤淋巴增殖性疾病中均有表达。然而,上皮膜抗原免疫反应性在CD30+继发性皮肤大细胞淋巴瘤中更常表达。在CD30+原发性皮肤大细胞淋巴瘤中,CD15表达仅见于局限性皮肤病变。P53表达与自发消退、皮肤外播散或生存无关。巢式逆转录聚合酶链反应在26例CD30+原发性皮肤大细胞淋巴瘤中的10例以及11例继发性皮肤大细胞淋巴瘤中的3例中检测到NPM-ALK转录本。在50例原发性和15例继发性皮肤CD30+淋巴增殖性疾病中,仅分别有1例和4例检测到ALK蛋白。在CD30+原发性皮肤淋巴增殖性疾病中,NPM-ALK转录本可能由免疫组织化学无法检测到的极罕见的正常或肿瘤细胞表达。然而,在CD30+皮肤淋巴增殖性疾病中,NPM-ALK转录本或ALK蛋白的表达与预后或年龄均无相关性。